[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.240.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 446
Citations 0
Research Letter
January 2, 2020

Methotrexate for the Treatment of Recalcitrant Erosive Lichen Planus of the Vulva

Author Affiliations
  • 1Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina
  • 2Department of Dermatology, Hospital Universitario Dr José E. Gonzalez, Universidad Autónoma de Nuevo León, Monterrey, Mexico
  • 3Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina
JAMA Dermatol. Published online January 2, 2020. doi:10.1001/jamadermatol.2019.4062

Erosive lichen planus of the vulva (ELPV) is a subtype of lichen planus characterized by desquamative, erosive dermatitis involving the vulva and vagina. Management of ELPV is challenging; almost 25% of patients have ELPV that is resistant to first-line therapy with topical corticosteroids.1,2 There are very few studies of ELPV, which makes management of recalcitrant ELPV difficult. Specifically, little evidence is available on methotrexate (MTX) for the treatment of recalcitrant ELPV. The aim of this study was to retrospectively review medical records to evaluate the efficacy of treatment with MTX in women with ELPV at a vulvar clinic.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×